ArticleMolecular biology reports2025
Investigation of the anticancer effects of doxorubicin-loaded niosomes on HCT-116 cells and the expression levels of LncRNAs DLGAP1-AS1 and AFAP1-AS1 in colorectal cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-coding RNAs: modulators of signaling pathways and prognostic biomarkers in digestive system cancer.Molecular cancer · 2026Review
- Long non-coding RNA POC1B-AS1 depletion represses colorectal cancer progression through the microRNA-625-5p/FOXK1 axis.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most common cancers worldwide and is often treated with chemotherapy. However, systemic toxicity, non-specificity, and drug resistance are major challenges associated with chemotherapeutic drugs. Nanocarriers such as niosomes (NIOs) can enhance drug accumulation at the tumor site while minimizing systemic side effects.
methodsDoxorubicin (DOX) was loaded into NIOs using the thin-film hydration method and characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR). HCT-116 colorectal cancer cells were treated with DOX and NIOs-DOX. Cell viability was assessed using the MTT assay. Additionally, apoptosis and cell cycle distribution were evaluated by flow cytometry, and the expression levels of DLGAP1-AS1 and AFAP1-AS1 were determined by quantitative real-time PCR (qRT-PCR).
resultsNIOs-DOX were synthesized with a size of 242.8 nm and a zeta potential of - 15.4 mV. The IC50 values of NIOs-DOX and DOX against HCT-116 cells were determined to be 0.974 µM and 4.18 µM, respectively. Flow cytometric analysis revealed a substantial increase in apoptotic cells in HCT-116 following treatment with NIOs-DOX compared to DOX. The expression levels of DLGAP1-AS1 and AFAP1-AS1 were significantly higher in tumor tissue samples than adjacent non-tumor samples. Furthermore, the overexpression of AFAP1-AS1 significantly correlated with the adenocarcinoma subtype. Based on the ROC curve analysis, DLGAP1-AS1 and AFAP1-AS1 expression showed poor diagnostic value.
conclusionNIOs-DOX demonstrated significant potential to enhance the therapeutic effects of DOX. Additionally, DLGAP1-AS1 and AFAP1-AS1 expression showed limited potential as diagnostic biomarkers in CRC.
Indexed as
Identifiers
40900234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.